Setiptiline

Setiptiline

SCHEMBL211362

CN1CCC2=C(C1)c1ccccc1Cc1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 9/20 1.00
DRD3 P35462 6/20 1.00
CHRM2 P08172 1/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00
CHRM1 P11229 1/20 1.00
SLC6A2 P23975 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRM1 P35372 1/20 1.00
SLC6A3 Q01959 1/20 1.00
KCNH2 Q12809 1/20 1.00
DRD5 P21918 8/20 0.60
DRD2 P14416 8/20 0.60
DRD4 P21917 8/20 0.60
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
ACHE P22303 1/20 0.53
SIGMAR1 Q99720 2/20 0.49
SETD7 Q8WTS6 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Setiptiline SCHEMBL29414110 1.00 DRD1 (1.00) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10728179 0.93 DRD1 (0.86) DRD1DRD3CHRM2HTR1AADRA2A
Setiptiline SCHEMBL29396748 0.87 DRD1 (0.76) DRD1DRD3CHRM2HTR1AADRA2A
Setiptiline SCHEMBL623015 0.87 DRD1 (0.76) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL13663060 0.84 DRD1 (0.73) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL12355565 0.84 DRD1 (0.73) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL10730066 0.81 DRD1 (0.69) DRD1DRD3CHRM2HTR1AADRA2A
Setiptiline SCHEMBL212453 0.78 DRD3 (0.72) DRD1DRD3CHRM2HTR1AADRA2A
SCHEMBL9306818 0.77 SIGMAR1 (0.64) DRD1DRD3CHRM2HTR1AADRA2A
Hydrochloric Acid SCHEMBL9308470 0.76 SIGMAR1 (0.67) DRD1DRD3CHRM2HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2360 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2026-04-23 US claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
EP-4633638-A1 TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) Luminous Mind Inc. (US) 2025-10-22 EP claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
EP-4497471-A2 STIMULATION OF NEURONAL PLASTICITY Institute of Science and Technology Austria (AT) 2025-01-29 EP claimed
EP-4479032-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS Sage Therapeutics, Inc. (US) 2024-12-25 EP claimed
US-20240408059-A1 METHOD OF TREATING ADDICTION ANEBULO PHARMACEUTICALS, INC. 2024-12-12 US claimed
US-20240307393-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT NATIONAL CANCER CENTER (KR) 2024-09-19 US claimed
US-20020037828-A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation VIVUS, INC. 2002-03-28 US claimed
US-20010008896-A1 Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation SMITH WILLIAM L (US) 2001-07-19 US claimed
EP-1109542-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-06-27 EP claimed
EP-1018879-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES Nitromed, Inc. (US) 2000-07-19 EP claimed
WO-2000012075-A1 NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-03-09 WO claimed
US-5922341-A Local administration of pharmacologically active agents to treat premature ejaculation VIVUS, INCORPORATED (US) 1999-07-13 US claimed
WO-1997027749-A1 NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES NITROMED, INC. (US) 1997-08-07 WO claimed
EP-0431663-B1 Stabilized solutions of psychotropic agents AKZO NV (NL) 1994-01-12 EP claimed
US-5082864-A STABILIZED SOLUTIONS OF PSYCHOTROPIC AGENTS AKZO N.V. (NL) 1992-01-21 US claimed
EP-0431663-A1 Stabilized solutions of psychotropic agents Akzo Nobel N.V. (NL) 1991-06-12 EP claimed